Lerociclib not checked

Genor Biopharma · G1T38 · GB491

FollowEvery change as it happens, and a Monday email
Next date
None yet
 
Trials
1 active
8 in total
Targets
—
None known yet

What this is

How it works
Blocks CDK enzymes that let cells divide, to slow the growth of cancer cells.-ciclib: cyclin-dependent kinase inhibitors WHO name stem
How it’s given
“Patients were randomized to receive GB491 150 mg orally twice daily, depending on their assignment. Letrozole 2.5 mg orally once a day from the first day of cycle 1 (one cycle every 28 days)”In the company’s words, NCT05851014 on ClinicalTrials.gov
Tested for
Breast Cancer
Main trialPhase 3
“The main purpose of this study is to evaluate the efficacy and safety of GB491 combined with Letrozole versus placebo combined with Letrozole in the treatment of HR+/HER2- locally advanced or metastatic breast cancer without prior systemic antitumor therapy”In the company’s words, NCT05851014 on ClinicalTrials.gov
Other names
G1T38 · GB491 · test drug + Fulvestrant

Other drugs for Breast Cancer

All 397 drugs for Breast Cancer

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials8

TrialPhaseCompletesWhat it tests
Phase 3Recruiting 30 Jan 2026 A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer
Phase 3Completed 2 Dec 2022 GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer
Phase 3Withdrawn Mar 2024 Comparison of Letrozole With Lerociclib Versus Letrozole With Placebo Control in Patients With Advanced/Metastatic or Recurrent, Grade 1 or Grade 2 Endometrial Cancer
Phase 2Terminated 29 Nov 2023 A Study of Lerociclib in Participants With Advanced Breast Cancer
Phase 1/2Completed 14 Dec 2021 G1T38, a CDK 4/6 Inhibitor, in Combination With Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer
Phase 1/2Unknown Jun 2023 G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
Phase 1Completed 14 Nov 2022 A Study of [14C]GB491 in Male Healthy Subjects
Phase 1Unknown 12 Dec 2023 A Phase Ib Study of GB491 Plus Letrozole in Patients With Advanced Breast Cancer
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Lerociclib

Following is part of Solo: you see every change to Lerociclib the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in